[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367937-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367937-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","when-rarity-meets-thoracic-cancers-a-narrative-review-from-itmig-2024","When Rarity Meets Thoracic Cancers - A Narrative Review from ITMIG 2024","","Rare thoracic cancers (RTCs) form a highly heterogeneous group of malignancies with low incidence, extensive histologic diversity, and major clinical obstacles. Their scarcity contributes to delayed diagnosis, inconsistent therapeutic strategies, and a limited number of prospective trials, further intensified by expertise fragmentation across institutions. This narrative review summarizes three representative RTC models highlighted at the 2024 ITMIG annual meeting, outlining distinctive clinical and pathological features and discussing approaches to optimize multidisciplinary care through centralized registries and tailored treatment strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/when-rarity-meets-thoracic-cancers-a-narrative-review-from-itmig-2024/367937/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/when-rarity-meets-thoracic-cancers-a-narrative-review-from-itmig-2024/367937.png","ImageObject",300,407,{"name":42,"@type":43},"Guten tag","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes rare thoracic cancers clinically challenging?","Question",{"text":63,"@type":64},"They are characterized by low incidence, high histological diversity, delayed diagnosis, limited standardized therapies, and scarce prospective clinical trials.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What was the review method used to gather evidence?",{"text":68,"@type":64},"A narrative review used targeted searching of PubMed, MEDLINE, and major conference proceedings up to January 2025, focusing on RTCs highlighted at the 2024 ITMIG annual meeting.",{"name":70,"@type":61,"acceptedAnswer":71},"Which three representative RTC models are emphasized?",{"text":72,"@type":64},"SMARCA4-deficient undifferentiated tumors, thymic neuroendocrine neoplasms, and mediastinal germ cell tumors are used to illustrate distinct and shared clinical and biological themes.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367937,1790435160,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687212321768,"https://ap-avatar.wpscdn.com/avatar/a0010bdbe886d2fe77?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789897067658708522","Review Article  \nWhen rarity meets thoracic cancers: a narrative review from ITMIG 2024  \nMargaret Ottaviano1^, Paolo Antonio Ascierto1, Erica Pietroluongo2  \n1Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”, Naples, Italy; 2Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy  \nContributions: (I) Conception and design: M Ottaviano; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: M Ottaviano, E Pietroluongo; (V) Data analysis and interpretation: M Ottaviano, E Pietroluongo; (VI) Manuscript  \nwriting: All authors; (VII) Final approval of manuscript: All authors.  \nCorrespondence to: Margaret Ottaviano, MD, PhD. Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori-IRCCS Fondazione “G. Pascale”, Via Mariano Semmola, 80131 Naples, NA, [Italy. Email: margaretottaviano@gmail.com](Italy. Email: margaretottaviano@gmail.com).  \nBackground and Objective: Rare thoracic cancers (RTCs) comprise a heterogeneous group of malignancies characterized by low incidence, high histological diversity, and significant clinical challenges.  \nTheir rarity often results in delayed diagnoses, lack of standardized therapeutic approaches, and limited prospective clinical trials. The absence of robust data is compounded by the fragmentation of expertise across institutions, underscoring the need for centralized, multidisciplinary management and international collaboration. This article aims to provide an overview of three representative RTC models, highlighting their unique clinical, pathological, and therapeutic features, and to discuss strategies for optimizing clinical  \ncare.  \nMethods: A narrative review was conducted based on a targeted search of PubMed, MEDLINE, and major conference proceedings up to January 2025. The search focused on selected RTCs highlighted during the 2024 ITMIG annual meeting, using terms such as “SMARCA4-deficient undifferentiated tumors”,“thymic neuroendocrine neoplasms”, and “mediastinal germ cell tumors”. Eligible sources included case reports,  \nretrospective series, and narrative reviews. Only English-language publications were considered.  \nKey Content and Findings: We focus on SMARCA4-deficient undifferentiated tumors as examples of rare entities newly defined by molecular profiling; thymic neuroendocrine neoplasms as ultra-rare and biologically aggressive neoplasms; and mediastinal germ cell tumors, which share biological traits with their gonadal counterparts but exhibit unique clinical behaviors. Through these models, we highlight common themes in RTCs management, including diagnostic uncertainty, limited therapeutic options, and emerging  \ndirections.  \nConclusions: We discuss the strengths and limitations of current evidence and future perspectives aimed  \nat enhancing outcomes through dedicated registries and tailored therapeutic strategies.  \nKeywords: Rare thoracic cancers (RTCs); SMARCA4-deficient tumors; thymic neuroendocrine neoplasms  \n(TNENs); mediastinal germ cell tumors (mediastinal GCTs)  \nReceived: 15 April 2025; Accepted: 28 July 2025; Published online: 25 September 2025.  \ndoi: 10.21037/med-25-22  \nView this article at: [https://dx.doi.org/10.21037/med-25-22](https://dx.doi.org/10.21037/med-25-22)  \n^ ORCID: 0000-0001-9589-0808.  \nCopyright © 2025 AME Publishing Company. All rights reserved. Mediastinum 2025;9:23 | [https://dx.doi.org/10.21037/med-25-22](https://dx.doi.org/10.21037/med-25-22)  \nPage 2 of 12 Mediastinum, 2025  \nIntroduction  \nThoracic malignancies encompass over 100 different histotypes in the World Health Organization (WHO) 5th Classification of 2021, which covers tumors of the lung, thymus, heart, and pleura (1) . Rare cancers, as defined by the European Rare Cancer Surveillance Project (RARECARE), represent a highly heterogeneous group of diseases ","cbCaiqnNsrQw2dCd","https://ap.wps.com/l/cbCaiqnNsrQw2dCd","pdf",204150,12,"English","# Introduction\n## Background on rare thoracic cancers\n# Methods\n## Targeted literature search scope and eligibility\n# Key Content and Findings\n## SMARCA4-deficient undifferentiated tumors\n## Thymic neuroendocrine neoplasms\n## Mediastinal germ cell tumors\n# Conclusions\n## Evidence limitations and future directions","[{\"question\":\"What makes rare thoracic cancers clinically challenging?\",\"answer\":\"They are characterized by low incidence, high histological diversity, delayed diagnosis, limited standardized therapies, and scarce prospective clinical trials.\"},{\"question\":\"What was the review method used to gather evidence?\",\"answer\":\"A narrative review used targeted searching of PubMed, MEDLINE, and major conference proceedings up to January 2025, focusing on RTCs highlighted at the 2024 ITMIG annual meeting.\"},{\"question\":\"Which three representative RTC models are emphasized?\",\"answer\":\"SMARCA4-deficient undifferentiated tumors, thymic neuroendocrine neoplasms, and mediastinal germ cell tumors are used to illustrate distinct and shared clinical and biological themes.\"}]","When Rarity Meets Thoracic Cancers - A Narrative Review from ITMIG 2024 | PDF",1790173412,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f4f36e72c86eed58c5abb97c8234e96.webp",983,1287,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/264efa43ddd319f9dd0e2d9706fc57c3.webp",982,1286,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/60644d0e45a25c40d54b5d606449092e.webp",981,1284,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c856589c8f574986bcc6ddb7f82ccbf4.webp",980,1283]